iShares Genomics Immunology and Healthcare ETF
IDNA
47 hedge funds and large institutions have $44.1M invested in iShares Genomics Immunology and Healthcare ETF in 2025 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 17 increasing their positions, 11 reducing their positions, and 7 closing their positions.
55% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 11
0.87% more ownership
Funds ownership: 40.86% → 41.73% (+0.87%)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
1% less capital invested
Capital invested by funds: $44.4M → $44.1M (-$290K)
2% less funds holding
Funds holding: 48 → 47 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PGA
Portland Global Advisors
Portland,
Maine
|
+$2.06M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$970K |
| 3 |
FTUS
Flow Traders U.S.
New York
|
+$914K |
| 4 |
Jane Street
New York
|
+$888K |
| 5 |
Raymond James Financial
St Petersburg,
Florida
|
+$208K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$4.12M |
| 2 |
CCA
Clearwater Capital Advisors
Hoffman Estates,
Illinois
|
-$373K |
| 3 |
Lido Advisors
Los Angeles,
California
|
-$319K |
| 4 |
CPRC
Consolidated Portfolio Review Corp
Woodbury,
New York
|
-$260K |
| 5 |
OIA
OneDigital Investment Advisors
Overland Park,
Kansas
|
-$205K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Comerica Bank
Dallas,
Texas
| – | -$6.17K | -301 | Closed |
|
|
TCM
52
TD Capital Management
Memphis,
Tennessee
| – | -$4.85K | -237 | Closed |
|
|
WIM
53
Westside Investment Management
Santa Monica,
California
| – | -$3.07K | -150 | Closed |
|
|
PA
54
Parallel Advisors
San Francisco,
California
| – | -$63 | -3 | Closed |
|
IDNA Hedge Fund Activity: Q2 2025 in Review
47 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in iShares Genomics Immunology and Healthcare ETF (IDNA) for Q2 2025, worth a combined $44.1M — down 0.65% from $44.4M a quarter earlier.
Fund positioning in IDNA was balanced in Q2 2025: 7 funds opened new positions, 7 closed out, 17 added to existing stakes and 11 trimmed.
The largest buyer was Portland Global Advisors, opening a new position worth an estimated $2.06M. The largest seller was Morgan Stanley, cutting an estimated $4.12M.
- 47 institutional investors held iShares Genomics Immunology and Healthcare ETF (IDNA) as of Q2 2025, down from 48 in Q1 2025.
- Funds reported $44.1M of iShares Genomics Immunology and Healthcare ETF stock for Q2 2025, down 0.65% quarter-over-quarter.
- 7 funds opened new iShares Genomics Immunology and Healthcare ETF positions in Q2 2025 and 7 closed out, a net change of 0 holders.
- The largest iShares Genomics Immunology and Healthcare ETF buyer in Q2 2025 was Portland Global Advisors, an estimated $2.06M added.
- The largest iShares Genomics Immunology and Healthcare ETF seller in Q2 2025 was Morgan Stanley, an estimated $4.12M sold.
Based on aggregated 13F filings for Q2 2025.